WO2001060825A1 - Pyrrolopyrimidinone derivatives, process of preparation and use - Google Patents
Pyrrolopyrimidinone derivatives, process of preparation and use Download PDFInfo
- Publication number
- WO2001060825A1 WO2001060825A1 PCT/KR2001/000227 KR0100227W WO0160825A1 WO 2001060825 A1 WO2001060825 A1 WO 2001060825A1 KR 0100227 W KR0100227 W KR 0100227W WO 0160825 A1 WO0160825 A1 WO 0160825A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- nch
- dihydro
- pyrrolo
- compound
- Prior art date
Links
- 0 *c1c(*)[n](*)c2c1N=C(c1cc(*)ccc1*)NC2=O Chemical compound *c1c(*)[n](*)c2c1N=C(c1cc(*)ccc1*)NC2=O 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Definitions
- the invention relates to a series of pyrrolopyrimidinone derivatives of the formula (1), processes for their preparation, intermediates in their preparation, their use as therapeutic agents, and pharmaceutical compositions containing them,
- R' is H; C,-C 3 alkyl optionally substituted with one or more fluoro atoms; or C 3 -C 6 cycloalkyl;
- R 2 is H; a halogen atom; C,-C 6 alkyl optionally substituted with OH, C,-C 3 alkoxy, C 3 -C 6 cycloalkyl, or with one or more fluoro atoms; C 3 -C 6 cycloalkyl; C 2 -C 6 alkenyl; or C 2 -C 6 alkynyl;
- R 3 is H; C,-C 6 alkyl optionally substituted with OH, C,-C 3 alkoxy, C 3 -C 6 cycloalkyl, or with one or more fluoro atoms; C 3 -C ⁇ cycloalkyl; C 2 -C 6 alkenyl; or C 2 -C 6 alkynyl; R 4 is C,-C 6 alkyl optionally substituted with C 3 -C 6 cycloalkyl or with one or more fluoro atoms; C 2 -C 6 alkenyl; C 2 -C 6 alkynyl; or C 3 -C 6 cycloalkyl;
- R 5 is SO 2 NR 6 R 7 ; NHSO 2 NR 6 R 7 ; NHCOCONR 6 R 7 ; NHSO 2 R 8 ; NHCOR 8 ; or phenyl or heterocyclyl either of which is optionally substituted with one or more fluoro atoms or C — C 3 alkyl;
- R 6 and R 7 are each independently H or C,-C 6 alkyl optionally substituted with OH, CO 2 H, C,-C 3 alkoxy, C 3 -C 6 cycloalkyl, or with one or more fluoro atoms; or together with the nitrogen atom to which they are attached form either a mono-cyclic ring such as imidazole, aziridene (aziridine), azeridine (azetidine), pyrroiidine, piperidine, morpholine, piperazine and homopiperazine, or a bicyclic ring such as 2,5-diazabicyclo[2. 2. l]heptane and 3,
- R 8 is C,-C 6 alkyl optionally substituted with one or more fluoro atoms; or C 3 -C 7 cycloalkyl;
- R 9 is C,-C 6 alkyl optionally substituted with one or more halide atoms, OH,
- R 10 is H; or C,-C 4 alkyl optionally substituted with OH, NR"R 12 , one or more fluoro atoms, or with a nitrogen containing heterocyclic ring such as pyrroiidine, piperidine, piperazine, morpholine, pyrrole, and imidazole wherein nitrogen atom is directly bound to C -C 4 alkyl;
- R 11 and R 12 are each independently H or C,-C 4 alkyl;
- R 13 is H; C,-C 4 alkyl optionally substituted with one or more fluoro atoms; or C 3 -C 6 cycloalkyl;
- R 14 and R 15 are each independently H or C,-C 4 alkyl optionally substituted with one or more fluoro atoms; C 3 -C 6 cycloalkyl; or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, piperazinyl, or homopiperazinyl group wherein said group is optionally substituted with C,-C 3 alkyl.
- EP-A-0463756 and EP-A-0526004 disclose certain pyrazolo[4,3- ⁇ Jpyrimidin-7-ones as cGMP PDE inhibitors, useful in the treatment of cardiovascular disorders such as angina, hypertension and heart failure.
- International application WO 94/28902 discloses their use for the treatment of impotence.
- the compounds (1) of this invention are potent and selective inhibitors of cyclic guanosine 3',5' ⁇ monophosphate specific phosphodiesterase (cGMP specific PDE; PDE V) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of impotence (male erectile dysfunction), sexual dysfunction in female, and various cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
- cGMP specific PDE cyclic guanosine 3',5' ⁇ monophosphate specific phosphodiesterase
- cGMP levels are elevated, which in turn can give rise to beneficial vasodilatory, anti-vasospastic, anti-platelet, anti-neutrophil, natriuretic and diuretic activities as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF), nitrovasodilators, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT,.
- EDRF endothelium-derived relaxing factor
- NAF atrial natriuretic factor
- BNP brain natriuretic peptide
- CNP C-type natriuretic peptide
- endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT
- the compounds of this invention therefore have utility in the treatment of a number of disorders, including impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
- disorders including impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud
- this invention provides compounds of the formula (1) and pharmaceutically acceptable salts and solvates (e.g. hydrates) thereof,
- R', R 2 , R 3 , R 4 and R 5 are as previously defined.
- alkyl groups having three or more carbon atoms may be straight or branched chain.
- alkenyl or alkynyl groups having four or more carbon atoms, or alkoxy groups having three carbon atoms may be straight or branched chain.
- Compounds of the formula (1) may contain one or more asymmetric centers and thus can exist as enantiomers or diastereomers. It. is to be understood that the invention includes both mixtures and separate individual isomers of compounds of the formula (1). Furthermore certain compounds of the formula (1) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.
- radiolabelled derivatives of compounds of formula (1) which are suitable for biological studies.
- Compounds of the formula (1) wherein one or more basic nitrogen atoms are present may form pharmaceutically acceptable salts with acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, fumaric, lactic, maleic, succinic and tartaric acids.
- acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, acetic, citric, fumaric, lactic, maleic, succinic and tartaric acids.
- Compounds of the formula (1) may form pharmaceutically acceptable salts with metal ions, such as alkali metals for example sodium and potassium, or with an ammonium ion.
- metal ions such as alkali metals for example sodium and potassium, or with an ammonium ion.
- a preferred group of compounds of the formula (1) is that wherein
- R' is H; methyl; or ethyl
- R 2 is H; methyl; or a halogen atom
- R 3 is C -C 4 alkyl
- R 4 is ethyl; /.-propyl; or allyl;
- R 5 is SO 2 NR 6 R 7 ; or NHSO 2 R 8 ;
- R 6 and R 7 taken together with the nitrogen atom to which they are attached form a piperidino, piperazinyl or homopiperazinyl group wherein said group is substituted with R 9 ;
- R 8 is methyl;
- R 9 is C,-C 4 alkyl optionally substituted with one or more halide atoms, OH, CO 2 R 10 , or with a tetrazole group which is optionally substituted with C,-C 3 alkyl;
- R 10 is H.
- a particularly preferred group of compounds of the formula (1) is that wherein R' is methyl;
- R 2 is H
- R 3 is ethyl; ⁇ -propyl; 3-fluoropiOpyl; or cyclopropyl methyl;
- R 4 is ethyl; or /.-propyl
- R 5 is SO 2 R 6 R 7 ; or NHSO 2 R 8 ; R 6 and R 7 taken together with the nitrogen atom to which they are attached form a piperidino or piperazinyl group wherein said group is substituted with R 9 ; R 8 is methyl;
- R 9 is C,-C 4 alkyl optionally substituted with one or more fluoro or chloro atoms, CO 2 R 10 , or with a tetrazole group; R 10 is H.
- Especially preferred individual compounds of the invention include: 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-/7-propyl-l,6-di hydro-7H-pyrrolo[4,3-_/Jpyrimidin-7-one; 5-(5-(4-methylpiperazinylsulfonyl)-2- «-propoxyphenyl)-l -methyl-3- ⁇ .-propyl-l ,6- dihydro-7H-pyrrolo[4,3-_/]pyrimidin-7-one;
- this invention provides processes for the preparation of compounds of the formula (1) or pharmaceutically acceptable salts thereof.
- Compounds of the formula (1) may be prepared from compounds of the formula (2), (3) or (4):
- R 1 , R 2 , R 3 and R 4 are as previously defined, and X represents sulfonyl halide, cyano or amino group, and Y represents a halogen atom, preferably a chloro atom.
- the coupling reaction of compounds of the formula (2) with a compound of the formula (5) (wherein R 6 and R 7 are as previously defined) is generally carried out at 0 °C to room temperature for 1-24 hours in a suitable solvent such as a C -C 3 alkanol,' dichloromethane, DMF, or water using an excess amount of (5) or in the presence of an organic tertiary amine, preferably triethylamine to scavenge the acid by-product.
- a cyano group in the precursor compound may be transformed into the amidine functionality.
- the reaction can be affected by treating a cyano compound with saturated HCl gas in an anhydrous alcohol such as methanol and ethanol, at -20 ° to 0 °C, and the subsequent reaction of the resulting alkyl imidate intermediate with an appropriate amine at 0 °C to room temperature.
- (6) (O (8) (wherein R 8 is as previously defined, and Y represents a halogen atom, preferably a chloro atom) is conveniently carried out at 0 °C to room temperature for 1-24 hours in an inert anhydrous solvent such as dichloromethane or THF using an excess amount of (6), (7) or (8), in the presence of an organic tertiary amine, preferably triethylamine to scavenge the acid by-product.
- the sulfonyl halide of the formula (6), the carboxylic acid anhydride of the formula (7) and the acyl halide of the formula (8) are either commercially available or readily obtainable by conventional synthetic procedures.
- the cyano compounds of the formula (4) can be effectively converted to the corresponding tetrazole derivatives by reacting with NaN 3 in the presence of 77-Bu 3 SnCl as a Lewis acid at refluxing temperature in an anhydrous hydrocarbon solvent such as toluene.
- Compounds of the formula (2) may be prepared from compounds of the formula (9) by using known methods for the introduction of a sulfonyl halide group into an aromatic ring, for example, when halide represents a chloro atom, by the action of chlorosulfonic acid at 0 °C to room temperature for 3-24 hours without any solvent.
- the amines of the formula (3) can be readily obtained by reduction of the corresponding nitro compounds of the formula (10) using well-known methods such as catalytic hydrogenation in an alcoholic solvent, or tin(II) chloride reduction, and so on.
- the cyano compounds of the formula (4) may be readily prepared from the bromide compounds of the formula (11) by displacement of the bromide with CuCN at 150-200 °C in a high boiling solvent such as l-methyl-2-pyrrolidinone.
- R 1 , R 2 , R 3 and R 4 are as previously defined, and X represents hydrogen, nitro or bromide group
- a cyclization reaction is generally carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of an acid or a base in a suitable solvent such as an aqueous C,-C 4 alkanol, water, a halogenated hydrocarbon, or acetonitrile.
- a suitable solvent such as an aqueous C,-C 4 alkanol, water, a halogenated hydrocarbon, or acetonitrile.
- the cyclization may be affected by treatment of a compound of the formulae (12)-(14) with an inorganic or organic base such as sodium hydroxide, potassium carbonate or potassium tert-butoxide, in an alcoholic aqueous medium, preferably potassium tert-butoxide in tert-butanol at 60 °C to reflux temperature.
- halide atom for compounds of the formula (9) (wherein R 1 , R 3 and R 4 are as previously defined, and R 2 is halide), the introduction of a halide atom to compounds of the formula (12) is carried out prior to subsequent cyclization.
- Halogenations may be affected by applying appropriate conditions for each halide, for example, N-chlorosuccinimide (NCS) in a halogenated solvent such as CH 2 C1 2 at -10 °C to room temperature for chlorination, bromine in acetic acid in the presence of sodium acetate at room temperature for bromination, and iodine along with mercuric oxide (HgO) in a hydrocarbon solvent such as benzene at 0 °C to room temperature for iodination.
- NCS N-chlorosuccinimide
- HgO mercuric oxide
- Compounds of the formulae (12)-(14) may be prepared from compounds of the formula (15) and (16), (17) or (18), respectively:
- R 1 , R 2 , R 3 and R 4 are as previously defined, X represents hydrogen, nitro or bromide group and Y represents a hydroxyl group or a halogen atom, preferably a chloro atom.
- a catalyst such as 4-dimethylaminopyridine (DMAP)
- DMAP 4-dimethylaminopyridine
- dichloromethane dichloromethane
- the nitro compounds of the formula (17) can be efficiently prepared from compounds of the formula (16) by using known methods for the nitration of an aromatic ring, and the reaction is generally carried out using sodium nitrite or fuming nitric acid under a strongly acidic medium such as concentrated sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid, at -10 °C to room temperature for 1-24 hours.
- a strongly acidic medium such as concentrated sulfuric acid or trifluoroacetic acid, preferably trifluoroacetic acid, at -10 °C to room temperature for 1-24 hours.
- Amide formation may be affected by using ammonia either in an alcoholic solvent or water, preferably water, at room temperature to 100 °C, in the presence or absence of sodium cyanide as a catalyst.
- a cyclization reaction is effectively carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of a base in a suitable solvent such as aqueous C,-C 4 alkanol or acetonitrile.
- a suitable solvent such as aqueous C,-C 4 alkanol or acetonitrile.
- the cyclization may be affected by treatment of a compound of the formula (20) with an alkoxide base such as sodium ethoxide or potassium tert-butoxide, in an alcoholic medium, preferably sodium ethoxide in ethanol at 60 °C.
- an alkoxide base such as sodium ethoxide or potassium tert-butoxide
- an alcoholic medium preferably sodium ethoxide in ethanol at 60 °C.
- Compounds of the formula (20) may be prepared from compounds of the formula
- a condensation reaction between compounds of the fonnula (21) and (22) is generally performed in a mixture of an alcohol and water, preferably methanol alone, in the presence of a weak base such as sodium acetate, at room temperature for 1-3 days.
- Compounds of the formula (21) are either commercially available or readily obtainable from glycine using well-documented synthetic methods.
- R 2 and R 3 are as previously defined, and R is C,-C 3 alkyl.
- Acylation reaction of compounds of the formula (23) is efficiently carried out by trapping the anionic species of compounds of the formula (23) with compounds of the formula (24) at -78 °C to room temperature.
- Generation of the anionic intermediate from compounds of the formula (23) may be affected by the action of a strong amide base such as sodium amide, alkali metal hexamethyldisilazide (Li, Na, or KHMDS) or lithium diisopropylamide (LDA), preferably LDA, in an anhydrous etheral solvent such as tetrahydrofuran, at low temperature, ranging from -78 ° to 0 °C.
- a strong amide base such as sodium amide, alkali metal hexamethyldisilazide (Li, Na, or KHMDS) or lithium diisopropylamide (LDA), preferably LDA
- anhydrous etheral solvent such as tetrahydrofuran
- R 1 , R 2 , R 3 and R 4 are as previously defined, and R 16 is a group R 5 as hereinbefore defined or a precursor to a group R 5 .
- a cyclization reaction is generally carried out by heating at an elevated temperature, for example 50-150 °C, in the presence of an acid or a base in a suitable solvent such as an aqueous C,-C 4 alkanol, water, a halogenated hydrocarbon, or acetonitrile.
- a suitable solvent such as an aqueous C,-C 4 alkanol, water, a halogenated hydrocarbon, or acetonitrile.
- the cyclization may be affected by treatment of a compound of the formula (25) with an inorganic or organic base such as sodium hydroxide, potassium carbonate or potassium tert-butoxide, in an aqueous alcoholic medium.
- R' 6 being a precursor to a group R 5 are when R 5 contains a carboxylic acid since an ester group of the formula (25) can be converted to the corresponding carboxylic acid under the basic cyclization condition.
- R 1 , R 2 , R 3 , R 4 and R 16 are as previously defined, and Y represents a hydroxyl group or a halogen atom, preferably a chloro atom.
- a catalyst such as 4-dimethylaminopyridine (DMAP)
- DMAP 4-dimethylaminopyridine
- Amines of the formula (5) when not commercially available, can be prepared by conventional synthetic procedures, in accordance with literature precedents, from readily accessible starting materials using standard reagents and reaction conditions.
- Z is a group CF 3 , hydroxyl, or a halogen, preferably fluoro atom and P represents an appropriate protecting group, for example, benzyl, benzyloxycarbonyl (Cbz) or tert-butoxycarbonyl (Boc).
- Removal of benzyl or benzyloxycarbonyl (Cbz) group in the compounds of the formula (27) can be performed under a hydrogenation condition using a catalytic amount of palladium on carbon in an alcoholic solvent such as methanol or ethanol, at room temperature to afford the corresponding compound of the formula (5).
- Cleavage of tert-butoxycarbonyl (Boc) group in the compounds of the formula (27) can be affected under the acidic conditions using aqueous HCl or trifluoroacetic acid in an aprotic solvent such as tetrahydrofuran or dichloromethane at room temperature to afford the corresponding salt of the formula (5).
- Starting materials of the formula (27) can be prepared from 1-benzylpiperazine or
- 1-tert-butoxycarbonylhomepiperazine of the formula (28) by direct N-alkylation with an appropriate alkyl halide containing a CF 3 , hydroxyl or halogen group.
- X is a group methine or nitrogen atom and P represents an appropriate protecting group, for example, preferably tert-butoxycarbonyl (Boc).
- Removal of tert-butoxycarbonyl (Boc) and triphenylmethyl (Trityl) groups in the compounds of the formula (29) can be affected simultaneously under the acidic conditions using aqueous HCl or trifluoroacetic acid in an aprotic solvent such as tetrahydrofuran at room temperatm-e, in the presence of excess lH-tetrazole as a carbocation scavenger, to afford the corresponding salt of the formula (5).
- aprotic solvent such as tetrahydrofuran at room temperatm-e
- Conversion of the cyano group of the formula (30) is generally affected by using tributyltin chloride and sodium azide in a hydrocarbon solvent, preferably toluene, at refluxing temperature to afford corresponding tetrazole compounds of the formula (29).
- Compounds of the formula (30) are readily prepared either from 1-tert-butoxycarbonylpiperazine of the formula (31) by direct N-alkylation with an appropriate alkyl halide containing a cyano group, or by conversion of the hydroxyl functionality of the formula (32) to a cyano group, using well-documented procedures.
- Starting materials of the formula (31) and (32) are either commercially available or readily accessible by conventional synthetic procedures in accordance with literature precedents.
- the resulting compounds of this invention represented by the formula (l)-(5), (9)-(15) and (19)-(22), can be separated and purified by appropriate conventional methods such as column chromatography and recrystallization.
- Compounds of the invention may be administered by any suitable route, for example by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration.
- oral, buccal or sub-lingual dosages of a compound of the formula (1) will generally be in the range of from 0. 1-400 mg daily for an average adult patient (70 Kg).
- individual tablets or capsules contain from 0. 05-200 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day.
- Dosages for parenteral administration will typically be within the range of from 0. 01-100 mg per single dose as required.
- the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
- the above dosages are exemplary of the average case but there can be . individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
- a compound of the formula (1) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- the compound may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents.
- Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agent (e. g.
- a compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously oiintracoronarily.
- the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.
- the invention provides in a further aspect a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (1), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier therefor.
- the invention also provides a compound of the formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for use in the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
- a compound of the formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for use in the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal
- the invention further provides the use of a compound of the formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous trans luminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome).
- a compound of the formula (1) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension
- the invention provides a method of treating or preventing impotence, sexual dysfunction in female, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e. g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma and diseases characterized by disorders of gut motility (e. g. irritable bowel syndrome), in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (1), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity.
- a mammal including a human being
- the invention also includes any novel intermediates of the formulae (2)-(4), (9)-(15) and (25) disclosed herein.
- the titled compound was prepared as described in Preparative Example 3 by using l-bromo-3-fluoropropane in place of l-bromo-2-fluoroethane. yield: 76%
- the titled compound was prepared as described in Preparative Example 4 by using l-tert ⁇ butoxycarbonyl-4-(3-fluoro-/.-propyl)homopiperazine in place of l-tert-butoxycarbonyl-4-(2-fluoroethyl)homopiperazine. yield: 88% mp 194-195 °C (Et 2 O/MeOH);
- the titled compound was prepared as described in Preparative Example 7 by using 2-cyano-5-fluoropentanal and N-methylglycine methyl ester hydrochloride in place of 2-cyanopentanal and N-methylglycine ethyl ester hydrochloride. yield: 73%
- the titled compound was prepared as described in Preparative Example 7 by using 3-cyclopropyl-2-cyanopropionaIdehyde and N-methylglycine methyl ester hydrochloride in place of 2-cyanopentanal and N-methylglycine ethyl ester hydrochloride. yield: 70%
- the titled compound was prepared as described in Preparative Example 1 1 by using N-(2-cyano-2-(cyclopropylmethyI)vinyl)-N-methyIglycine methyl ester in place of N-(2-cyano-2-w-propylvinyl)-N-methylglycine ethyl ester. yield: 85% mp 100.5-102°C (CH,Cl 2 /ether);
- the titled compound was prepared as described in Preparative Example 15 by using N-(2-cyano-2-ethylvinyl)-N-methylglyclne amide in place of
- the titled compound was prepared as described in Preparative Example 15 by using N-(2-cyano-2-(cyclopropylmethyl)vinyl)-N-methylglycine amide in place of
- the titled compound was prepared as described in Preparative Example 21 by using 4-amino-:3-(3-_luoiOpropyl)-l-methylpyrroIe-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 21 by using 4-amino-3-cyclopropylmethyl- l-methylpyrrole-5-carboxamide in place of 4-amino-3-ethyl-l-metl ylpyrrole-5-carboxamide. yield: 91 % mp 198-199 °C (CH,Cl 2 /ether);
- R 4 CH 2 CH 2 CH 3 )
- the titled compound was prepared as described in Preparative Example 12 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)- 1 -methyl-3 -/7-propy lpyrrole-5 -carboxamide. yield: 94% mp 108-108. 5 °C (CHCl 3 /Et 2 O/hexanes);
- the titled compound was prepared as described in Preparative Example 14 by using l-methyl-5-(2-77-propoxyphenyl)-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4,3-c]pyrimidin- 7-one in place of 5-(2-ethoxyphenyl)-
- the titled compound was prepared as described in Preparative Example 10 by using 2-(2-fluoroethoxy)benzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 67% mp 132-132. 5 °C (ethyl acetate/hexanes); IR (neat) 3344, 3164 (NH), 1664, 1640 (CO) cm '1 ;
- the titled compound was prepared as described in Preparative Example 14 by using 5-(2-(2-fluoiOethoxy)phenyl)-l-methyl-3-77-propyl-l,6-dihydiO-7H-pyrrolo[4,3-(i]pyri midin-7-one in place of
- the titled compound was prepared as described in Preparative Example 10 by using 4-amino-l,2-dimethyl-3-77-propylpyrrole-5-carboxamide in place of 4-amino-2-methyl-3-77-propylpyrrole-5-carboxamide. yield: 73% mp 171. 5 °C dec (CHCl 3 /Et 2 O/hexanes);
- the titled compound was prepared as described in Preparative Example 10 by using 4-amino-l ,2-dimethyl-3-77-propylpyrrole-5-carboxamide and
- the titled compound was prepared as described in Preparative Example 17 by using l,2-dimethyl-4-(2-ethoxybenzamido)-3-77-propylpyriOle-5-carboxamide in place of 4-(2-(2-fluoroethoxy)benzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 94% mp 130 °C dec (CHCyE ⁇ O/hexanes);
- the titled compound was prepared in a slightly impure form as described in Preparative Example 14 by using 1 ,2-dimethyl-5-(2-77-propoxyphenyl)-3-77-propyl- 1 ,6-dihydro-7H-pyrrolo[4,3- ⁇ T]pyrimi din-7-one in place of
- the titled compound was prepared as described in Preparative Example 17 by using 2-chloro-4-(2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 4-(2-(2-fluoroethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide. yield: 70% mp 145. 5—146 °C (ethyl acetate/hexanes);
- the titled compound was prepared as described in Preparative Example 34 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)-l-methyl-3-77-piOpylpyrrole-5-carboxamide. yield: 85% mp 142-143 °C (CHCl 3 /Et 2 O/hexanes);
- the titled compound was prepared as described in Preparative Example 17 by using 2-bromo-4-(2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 4-(2-(2-fluoiOethoxybenzamido)- 1 -methyl-3-/7-propylpyrrole-5-carboxamide. yield: 100% mp 152. 5-153 °C (ethyl acetate/hexanes); IR (neat) 3311 (NH), 1679 (CO) cm '1 ;
- the titled compound was prepared as described in Preparative Example 34 by using l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of 4-(2-ethoxybenzamido)-l-methyl-3-77-propylpyrrole-5-carboxamide. yield: 82% mp 169. 5-170 °C (ethyl acetate/hexanes);
- the titled compound was prepared as described in Preparative Example 17 by using 4-(2-ethoxybenzamido)-2-iodo-l -methyl-3-77-propylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 17 by using 2-iodo-l-methyl-4-(2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 46 by using 5-(5-chloros ⁇ lfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyiOlo[ 4,3-_/
- the titled compound was prepared as described in Preparative Example 46 by using 4-(2-cyanoethyl)piperidine trifluoroacetic acid in place of 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 76% mp 225-225. 5 °C (EtOH/ CHC1 3 );
- NR 6 R 7 is 4-(2-cyanoethyl)piperidinyl)
- the titled compound was prepared as described in Preparative Example 46 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-piOpyl-l,6-dihydro-7H-pyrolo[
- the titled compound was prepared as described in Preparative Example 46 by using 4-(ethoxycarbonylmethyl)piperidine in place of 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 74% mp 146-147 °C (EtOAc/hexanes);
- NR ⁇ R 7 is 4-(ethoxycarbonyhnethyl)piperidinyl)
- the titled compound was prepared as described in Preparative Example 46 by using
- the titled compound was prepared as described in Preparative Example 46 by using 4-(2-ethoxycarbonylethyl)piperidine in place of 4-(cyanomethyl)piperidine trifluoroacetic acid, yield: 77% mp 139. 5-140 °C (EtOAc/hexanes);
- the titled compound was prepared as described in Preparative Example 46 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[ 4,3-_ ]pyrimidin-7-one and 4-(2-ethoxycarbonylethyl)piperidine in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrolo[4,3 -ct]pyrimidin-7-one and 4-(cyanomethyl)piperidine trifluoroacetic acid. yield: 80% mp 134-135 °C (EtOAc/C ⁇ Cl 3 );
- NR 6 R 7 is ((S)-l-benzyloxycarbonyl-2-methylpropyl)amino)
- the titled compound was prepared as described in Preparative Example 46 by using L-valine benzyl ester hydrochloride in place of 4-(cyanomethyl)piperidine trifluoiOacetic acid. yield: 79% mp 103-104 °C (EtOAc/Et 2 O/hexanes);
- the titled compoimd was prepared as described in Preparative Example 10 by using 2-ethoxy-5-nitrobenzoyl chloride in place of 2-ethoxybenzoyl chloride, yield: 96% mp 227-227. 5 °C (CHCl 3 /Et 2 O); IR (neat) 3447, 3299 (NH), 1657, 1639 (CO), 1341, 1288 (NO 2 ) cm '1 ;
- the titled compound was prepared as described in Preparative Example 10 by using 5-nitro-2-77-propoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride, yield: 94% mp 224-224. 5 °C (CHCl 3 /Et,O);
- the titled compound was prepared as described in Preparative Example 17 by using 1 -methyl-4-(5-nitro-2-77-propoxybenzamido)-3-77-propylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 60 by using l-methyl-4-(5-nitiO-2-77-propoxybenzamido)-3-77-piOpylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 10 by using 5-bromo-2-ethoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 98% mp 158-159 °C (EtOAc/Et 2 O/hexanes);
- the titled compound was prepared as described in Preparative Example 10 by using 5-bromo-2-77-propoxybenzoyl chloride in place of 2-ethoxybenzoyl chloride. yield: 89% mp 148-150 °C (CHCl 3 /hexanes);
- the titled compound was prepared as described in Preparative Example 17 by using 4-(5-bromo-2-ethoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Preparative Example 66 by using 4-(5-cyano-2-77-propoxybenzamido)- 1 -methyl-3-77-propylpyrrole-5-carboxamide in place of 5-(5-cyano-2-ethoxyphenyl)-l-methyl-3-77-propyl-l ,6-dihydro-7H-pyrrolo[4,3- ⁇ j/]pyri midin-7-one. yield: 84% mp 179-180. 5 °C (C ⁇ Cl 3 /hexanes);
- the titled compoimd was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)- 1 -methyl-3 -77-propyl- 1 ,6-dihydro-7H-pyrrolo [4,3-t/]pyrimidin-7-one in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3-_/Jpyrimidin-7-one. yield: 81% mp 183-183.
- NR 6 R 7 is 4-methylpiperazinyl
- the titled compound was prepared as described in Example 2 by using 5-(5-(4-methylpiperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dih ydro-7H-pyrrolo[4,3- ⁇ fJpyrimidin-7-one in place of
- the titled compound was prepared as described in Example 1 by using 1-ethylpiperazine in place of 1-methylpiperazine. yield: 89% mp 200-200. 5 °C (CHCl 3 /EtOAc/hexanes);
- the titled compound was prepared as described in Example 1 by using 1-77-piOpylpiperazine in place of 1-methylpiperazine. yield: 76% mp 202. 5 °C dec (CHCl 3 /Et 2 O/hexanes);
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-77-piOpylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihyd ro-7H-pyrrolo[4,3- ⁇ ]pyrimidin-7-one in place of
- the titled compound was prepared as described in Example 1 by using 1-isopropylpiperazine in place of 1 -methylpiperazine. yield: 87% mp 241. 5 °C dec (CHCl 3 /Et 2 O);
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-isopropylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l ,6-dihy dro-7H-pyrrolo[4,3-d]pyrimidin-7-one in place of 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l -methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_f]pyrimidin-7-one. yield: 98% mp 244.
- the titled compound was prepared as described in Example 1 by using l-(2-fluoroethyl)piperazine hydrochloride in place of 1-methylpiperazine. yield: 92% mp 204. 5-205 °C (EtOAc/hexanes); IR (neat) 3335 (NH), 1678 (CO), 1 169 (SO 2 ) cm 1 ;
- NR 6 R 7 is 4-(2-fl ⁇ xoroethyl)piperazinyl)
- the titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo
- the titled compound was prepared as described in Example 2 by using 5-(5-(4-(2-fluoroethyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-propyl- l,6-dihydiO-7H-pyrrolo[4,3- ⁇ pyrimidin-7-one in place of
- the titled compound was prepared as described in Example 1 by using l-(3-fluoropropyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 85% mp 217. 5-218 °C (EtOAc/CHCl 3 /hexanes);
- the titled compound was prepared as described in Example 15 by using 4-(2-ethoxy-5-(4-(3-fluoropiOpyl)piperazinylsulfonyl)benzamido)-3-(3-fl ⁇ oropjOpyl)- l-methylpyrrole-5-carboxamide in place of
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5 -(4-(3 -fluoropropy l)piperazinylsulfony l)pheny 1)- 1 -methyl-3 -77-propy 1- 1 , 6-dihydro-7H-pyrrolo[4,3-_f]pyrimid_n-7-one in place of
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyI-l, 6-dihydiO-7H-pyrrolo[4,3-tt]pyrimidin-7-one and 10% ethanolic H 2 SO 4 solution in place of
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyl)piperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l , 6-dihydiO-7H-pyrrolo[4,3-_/]pyrimidin-7-one and 10%) ethanolic ⁇ 3 PO 4 solution in place of
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(3-fluoropropyI)piperazinylsuIfonyI)phenyl)-l-methyl-3-77-propyl-l, 6-dihydro-7H-pyriOlo[4,3- ⁇ fJpyrimidin-7-one and 10% C ⁇ 3 SO 3 ⁇ /C ⁇ ,Cl 2 solution in place of 5-(2-ethoxy-5-(4-methylpiperazinylsulfonyl)phenyl)-l-methyl-3-77-propyl-l,6-dihydro -7H-pyrrolo[4,3-_/]pyrimid_n-7-one and 1 N ⁇ C1 etheral solution, yield: 90% mp 74 °C dec; IR (neat) 3321 ( ⁇ ), 1683 (CO), 1173 (SO 2 ) cm '1 ;
- the titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo [4,3-_f]pyrimidin-7-one and 1 -(3-fluoropiOpyl)piperazine hydrochloride in place of 5-(5-chlorosulfonyl-2-ethoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyrrolo[4, 3- ]pyrimidin-7-one and 1-methylpiperazine. yield: 90% mp 154-154.
- the titled compound was prepared as described in Example 2 by using 5-(5-(4-(3-fluoropropyl)piperazinylsulfonyl)-2-77-propoxyphenyl)-l-methyl-3-77-piOpy l-l,6-dihydro-7H-pyrrolo[4,3-_/Jpyrimidin-7-one in place of
- the titled compound was prepared as described in Example 1 by using l-(l,3-difluoroisopropyl)piperazine hydrochloride in place of 1 -methylpiperazine ' . yield: 75% mp 218. 5-219 °C (CHCl EtOAc/hexanes); IR (neat) 3338 (NH), 1676 (CO), 1170 (SO,) cm '1 ;
- the titled compound was prepared as described in Example 1 by using 1 -(4-fluorobutyl)piperazine trifluoroacetic acid in place of 1 -methylpiperazine. yield: 53% mp 188-189 °C (EtOAc/CHCl 3 /hexanes);
- the titled compound was prepared as described in Example 1 by using l-(2,2,2-trifluoroethyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 80% mp 243-243. 5 °C (EtOAc/hexanes);
- NR 6 R 7 is 4-(2,2,2-trifluoiOethyl)piperazinyl)
- the titled, compound was prepared as described in Example 1 by using l-(3,3,3-trifluoropropy_)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 87% mp 219-220 °C (EtOAc/hexanes);
- NR 6 R 7 is 4-(3,3,3-trifluoropropyl) ⁇ iperazinyl)
- the titled compound was prepared as described in Example 1 by using 5-(5-chlorosulfonyl-2-77-propoxyphenyl)-l-methyl-3-77-propyl-l,6-dihydro-7H-pyriOlo
- the titled compound was prepared as described in Example 1 by using l-(2-chloroethyl)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 87% mp 226 °C dec (CHCl 3 /Et 2 O);
- the titled compound was prepared as described in Example 1 by using 1 -(3 -chloropropy l)piperazine hydrochloride in place of 1 -methylpiperazine. yield: 94% mp 203 °C dec (CHCl 3 /Et 2 O);
- the titled compound was prepared as described in Example 1 by using 1 -(2-hydroxyethyl)piperazine in place of 1 -methylpiperazine. yield: 99% mp 175 °C dec (EtOAc/hexanes);
- the titled compound was prepared as described in Example 2 by using 5-(2-ethoxy-5-(4-(2-hydroxyethyl)piperazinylsulfonyl)phenyl)- 1 -methyl-3-77-propy 1- 1 ,6-dihydro-7H-pyrrolo[4,3- ]pyrimidin-7-one in place of
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60103508T DE60103508T2 (de) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinon-derivate, verfahren zu ihrer herstellung und verwendung |
HU0300527A HU230344B1 (hu) | 2000-02-17 | 2001-02-15 | Pirrolopirimidinon-származékok, a vegyületek előállítása és alkalmazása |
PL358188A PL210796B1 (pl) | 2000-02-17 | 2001-02-15 | Pochodne pirolopirymidynonu, kompozycja farmaceutyczna, sposób ich otrzymywania oraz zastosowanie |
AU2001236140A AU2001236140B9 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
AU3614001A AU3614001A (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
JP2001560209A JP4845076B2 (ja) | 2000-02-17 | 2001-02-15 | ピロロピリミジン誘導体とその製造方法、およびそれを含有する薬学的組成物。 |
AT01908397T ATE267829T1 (de) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinon-derivate, verfahren zu ihrer herstellung und verwendung |
US10/204,327 US6962911B2 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
NZ520842A NZ520842A (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
IL15123401A IL151234A0 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives process of preparation and use |
EP01908397A EP1257553B1 (de) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinon-derivate, verfahren zu ihrer herstellung und verwendung |
BRPI0108395A BRPI0108395B8 (pt) | 2000-02-17 | 2001-02-15 | derivados de pirrolopirimidinona, processos de preparação e uso |
CA002400268A CA2400268C (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
MXPA02007942A MXPA02007942A (es) | 2000-02-17 | 2001-02-15 | Derivados de pirrolopirimidinona, procesos de preparacion y uso. |
NO20023823A NO323553B1 (no) | 2000-02-17 | 2002-08-13 | Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater |
IL151234A IL151234A (en) | 2000-02-17 | 2002-08-13 | History of pyrolopyrimidinone, preparation and use process |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2000/7625 | 2000-02-17 | ||
KR20000007625A KR100358083B1 (ko) | 2000-02-17 | 2000-02-17 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001060825A1 true WO2001060825A1 (en) | 2001-08-23 |
Family
ID=19647449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2001/000227 WO2001060825A1 (en) | 2000-02-17 | 2001-02-15 | Pyrrolopyrimidinone derivatives, process of preparation and use |
Country Status (23)
Country | Link |
---|---|
US (1) | US6962911B2 (de) |
EP (1) | EP1257553B1 (de) |
JP (1) | JP4845076B2 (de) |
KR (1) | KR100358083B1 (de) |
CN (1) | CN1312153C (de) |
AT (1) | ATE267829T1 (de) |
AU (2) | AU2001236140B9 (de) |
BR (1) | BRPI0108395B8 (de) |
CA (1) | CA2400268C (de) |
DE (1) | DE60103508T2 (de) |
DK (1) | DK1257553T3 (de) |
ES (1) | ES2222344T3 (de) |
HU (1) | HU230344B1 (de) |
IL (2) | IL151234A0 (de) |
MX (1) | MXPA02007942A (de) |
NO (1) | NO323553B1 (de) |
NZ (1) | NZ520842A (de) |
PL (1) | PL210796B1 (de) |
PT (1) | PT1257553E (de) |
RU (1) | RU2263676C2 (de) |
TR (1) | TR200402101T4 (de) |
WO (1) | WO2001060825A1 (de) |
ZA (1) | ZA200206587B (de) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1362858A1 (de) * | 2002-05-15 | 2003-11-19 | SK Chemicals Co., Ltd. | Pyrrolopyrimidinonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
WO2004108726A1 (fr) | 2003-06-06 | 2004-12-16 | Tianjin Tasly Group Co., Ltd. | Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie |
JP2005535646A (ja) * | 2002-07-03 | 2005-11-24 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | イミダゾトリアジノン類の新規用途 |
JP2006502999A (ja) * | 2002-07-26 | 2006-01-26 | グリーンファルマ | 新規置換ピラゾロ〔1,5‐a〕‐1,3,5‐トリアジン誘導体およびそれらの類似体、それを含有した医薬組成物、医薬品としてのその使用、およびその製造方法 |
WO2007040435A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. |
WO2012173689A3 (en) * | 2011-04-15 | 2013-04-04 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
US9193731B2 (en) | 2009-10-16 | 2015-11-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9573962B2 (en) | 2009-10-16 | 2017-02-21 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2017085056A1 (en) * | 2015-11-16 | 2017-05-26 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
US9845297B2 (en) | 2009-10-16 | 2017-12-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9937183B2 (en) | 2013-09-09 | 2018-04-10 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10106543B2 (en) | 2013-09-09 | 2018-10-23 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2018215433A1 (en) | 2017-05-22 | 2018-11-29 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
WO2020030489A1 (en) | 2018-08-06 | 2020-02-13 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
WO2020109354A1 (en) | 2018-11-28 | 2020-06-04 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
US10947237B2 (en) | 2015-03-11 | 2021-03-16 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
RU2774861C2 (ru) * | 2015-11-16 | 2022-06-23 | Топадур Фарма Аг | Производные 2-фенил-3,4-дигидропирроло[2,1-f][1,2,4]триазинона как ингибиторы фосфодиэстеразы и их применение |
WO2023052407A1 (en) | 2021-09-29 | 2023-04-06 | Topadur Pharma Ag | Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof |
WO2023166013A1 (en) | 2022-03-02 | 2023-09-07 | Topadur Pharma Ag | Topical compositions and uses therof |
WO2023167503A1 (ko) * | 2022-03-02 | 2023-09-07 | 연세대학교 산학협력단 | 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태 |
US11999739B2 (en) | 2016-05-06 | 2024-06-04 | BioVersys AG | Antimicrobials methods of making and using the same |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
KR20080003599A (ko) * | 2006-07-03 | 2008-01-08 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법 |
US20100069632A1 (en) * | 2006-07-03 | 2010-03-18 | Sk Chemicals Co., Ltd | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
KR101002490B1 (ko) * | 2007-06-09 | 2010-12-17 | 동아제약주식회사 | 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물 |
CN102970965A (zh) | 2010-04-05 | 2013-03-13 | Sk化学公司 | 含有pde5抑制剂的减少皮肤皱纹的合成物 |
CN102372730B (zh) * | 2010-08-19 | 2014-03-26 | 山东轩竹医药科技有限公司 | 桥环取代的磷酸二酯酶抑制剂 |
CN102134242B (zh) * | 2011-01-21 | 2013-08-28 | 浙江大德药业集团有限公司 | 一种用于治疗阳痿的快速长效的化合物 |
TWI490220B (zh) * | 2011-04-04 | 2015-07-01 | Sk Chemicals Co Ltd | 包含pde5抑制劑之用於減少皮膚皺紋之組成物 |
JP2014526461A (ja) * | 2011-09-09 | 2014-10-06 | エスケー ケミカルズ カンパニー,リミテッド | Pde5抑制剤を含む皮膚しわ改善用組成物 |
JP6120985B2 (ja) | 2012-12-04 | 2017-04-26 | アリビオ, インコーポレーテッド | ホスホジエステラーゼタイプ5活性阻害剤を含む神経細胞のアポトーシス抑制用組成物 |
CN104744478B (zh) * | 2015-03-20 | 2016-08-24 | 中国人民解放军第二军医大学 | 一种防治辐射损伤的化合物、单晶及其制备方法和应用 |
KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
CN111825593B (zh) * | 2020-08-19 | 2023-04-07 | 上海成澄科技有限公司 | 3-氨基吡咯-2-甲酰胺类化合物的合成方法 |
KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
KR20220140960A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
KR102311224B1 (ko) | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
KR20220146095A (ko) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5761734B2 (de) * | 1973-09-27 | 1982-12-25 | Takeda Chemical Industries Ltd |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5761734A (en) * | 1980-10-02 | 1982-04-14 | Teijin Ltd | Spun like fabric |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
JP3713783B2 (ja) * | 1995-01-20 | 2005-11-09 | 大正製薬株式会社 | 1H−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体 |
CZ299633B6 (cs) * | 1997-04-25 | 2008-09-24 | Pfizer Inc. | Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi |
TR200003039T2 (tr) * | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
-
2000
- 2000-02-17 KR KR20000007625A patent/KR100358083B1/ko active IP Right Grant
-
2001
- 2001-02-15 HU HU0300527A patent/HU230344B1/hu unknown
- 2001-02-15 JP JP2001560209A patent/JP4845076B2/ja not_active Expired - Lifetime
- 2001-02-15 TR TR2004/02101T patent/TR200402101T4/xx unknown
- 2001-02-15 AU AU2001236140A patent/AU2001236140B9/en not_active Expired
- 2001-02-15 AT AT01908397T patent/ATE267829T1/de active
- 2001-02-15 PT PT01908397T patent/PT1257553E/pt unknown
- 2001-02-15 DK DK01908397T patent/DK1257553T3/da active
- 2001-02-15 DE DE60103508T patent/DE60103508T2/de not_active Expired - Lifetime
- 2001-02-15 EP EP01908397A patent/EP1257553B1/de not_active Expired - Lifetime
- 2001-02-15 WO PCT/KR2001/000227 patent/WO2001060825A1/en active IP Right Grant
- 2001-02-15 US US10/204,327 patent/US6962911B2/en not_active Expired - Lifetime
- 2001-02-15 IL IL15123401A patent/IL151234A0/xx unknown
- 2001-02-15 RU RU2002124872/04A patent/RU2263676C2/ru active
- 2001-02-15 NZ NZ520842A patent/NZ520842A/en not_active IP Right Cessation
- 2001-02-15 PL PL358188A patent/PL210796B1/pl unknown
- 2001-02-15 CA CA002400268A patent/CA2400268C/en not_active Expired - Lifetime
- 2001-02-15 MX MXPA02007942A patent/MXPA02007942A/es active IP Right Grant
- 2001-02-15 BR BRPI0108395A patent/BRPI0108395B8/pt not_active IP Right Cessation
- 2001-02-15 CN CNB018075002A patent/CN1312153C/zh not_active Expired - Lifetime
- 2001-02-15 AU AU3614001A patent/AU3614001A/xx active Pending
- 2001-02-15 ES ES01908397T patent/ES2222344T3/es not_active Expired - Lifetime
-
2002
- 2002-08-13 IL IL151234A patent/IL151234A/en active IP Right Grant
- 2002-08-13 NO NO20023823A patent/NO323553B1/no not_active IP Right Cessation
- 2002-08-16 ZA ZA200206587A patent/ZA200206587B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5761734B2 (de) * | 1973-09-27 | 1982-12-25 | Takeda Chemical Industries Ltd |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 198304, Derwent World Patents Index; AN 1975-83762W, XP002955424 * |
J. HAUSLER: "Darstellung von cis- und trans-C-3-substituierten prolinverbundungen", LIEBIGS ANN. CHEM., 1981, pages 1073 - 1088, XP002955437 * |
T. MURATA ET AL.: "Intramolecular reactions of enaminonitriles. A new synthesis of beta-aminopyrroles and related heterocycles", CHEM. PHARM. BULL., vol. 26, no. 10, 1978, pages 3080 - 3100, XP002955436 * |
T. MURATA ET AL.: "Intramolecular reactions of enaminonitriles. II. Synthesis of new 3-aminopyrrole-2-carboxamides - A new route to pyrrolo(3,2-d)pyrimidines", CHEM. PHARM. BULL., vol. 22, no. 1, pages 240 - 241, XP002955444 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1362858A1 (de) * | 2002-05-15 | 2003-11-19 | SK Chemicals Co., Ltd. | Pyrrolopyrimidinonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
JP2005535646A (ja) * | 2002-07-03 | 2005-11-24 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | イミダゾトリアジノン類の新規用途 |
JP4794856B2 (ja) * | 2002-07-26 | 2011-10-19 | グリーンファルマ | 新規置換ピラゾロ〔1,5‐a〕‐1,3,5‐トリアジン誘導体およびそれらの類似体、それを含有した医薬組成物、医薬品としてのその使用、およびその製造方法 |
JP2006502999A (ja) * | 2002-07-26 | 2006-01-26 | グリーンファルマ | 新規置換ピラゾロ〔1,5‐a〕‐1,3,5‐トリアジン誘導体およびそれらの類似体、それを含有した医薬組成物、医薬品としてのその使用、およびその製造方法 |
US7741483B2 (en) | 2003-06-06 | 2010-06-22 | Yangtze River Pharmaceutical (Group) Co., Ltd. | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 |
JP2008500944A (ja) * | 2003-06-06 | 2008-01-17 | 天津天士力集団有限公司 | 2−置換フェニル−5,7−ジアルキル−3,7−ジヒドロピロロ[2,3−d]ピリミジン−4−オン誘導体、その製法およびその医薬用途 |
KR101081446B1 (ko) | 2003-06-06 | 2011-11-08 | 탄진 노쓰 파마 싸이-테크 컴퍼니 리미티드 | 2-치환페닐-5,7-디알킬-3,7-디하이드로피롤[2,3-d]피리미딘-4-온유도체, 그의 제법 및 약학적 용도 |
US8461165B2 (en) | 2003-06-06 | 2013-06-11 | Yangtze River Pharmaceutical (Group) Co., Ltd | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
WO2004108726A1 (fr) | 2003-06-06 | 2004-12-16 | Tianjin Tasly Group Co., Ltd. | Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie |
WO2007040435A1 (en) * | 2005-10-03 | 2007-04-12 | Astrazeneca Ab | Novel 5,6-dihydropyrazolo[3,4-e] [l,4]diazepin-4 (ih) -one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. |
US9573962B2 (en) | 2009-10-16 | 2017-02-21 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10259825B2 (en) | 2009-10-16 | 2019-04-16 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9193731B2 (en) | 2009-10-16 | 2015-11-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9845297B2 (en) | 2009-10-16 | 2017-12-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
CN109053695A (zh) * | 2011-04-15 | 2018-12-21 | 梅琳塔治疗公司 | 抗微生物化合物及制备和使用所述化合物的方法 |
CN103958514A (zh) * | 2011-04-15 | 2014-07-30 | 梅琳塔治疗公司 | 抗微生物化合物及制备和使用所述化合物的方法 |
US9221827B2 (en) | 2011-04-15 | 2015-12-29 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
CN103958514B (zh) * | 2011-04-15 | 2018-07-03 | 梅琳塔治疗公司 | 抗微生物化合物及制备和使用所述化合物的方法 |
WO2012173689A3 (en) * | 2011-04-15 | 2013-04-04 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
US9937183B2 (en) | 2013-09-09 | 2018-04-10 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10106543B2 (en) | 2013-09-09 | 2018-10-23 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10947237B2 (en) | 2015-03-11 | 2021-03-16 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
US11897890B2 (en) | 2015-11-16 | 2024-02-13 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
US11242347B2 (en) | 2015-11-16 | 2022-02-08 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1-Ff] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
US10570137B2 (en) | 2015-11-16 | 2020-02-25 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
RU2774861C2 (ru) * | 2015-11-16 | 2022-06-23 | Топадур Фарма Аг | Производные 2-фенил-3,4-дигидропирроло[2,1-f][1,2,4]триазинона как ингибиторы фосфодиэстеразы и их применение |
IL259163A (en) * | 2015-11-16 | 2018-07-31 | Topadur Pharma Ag | 2-Phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazinone derivatives as phosphodiesterase enzyme inhibitors and their uses |
AU2016355854B2 (en) * | 2015-11-16 | 2021-05-06 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
WO2017085056A1 (en) * | 2015-11-16 | 2017-05-26 | Topadur Pharma Ag | 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof |
US11999739B2 (en) | 2016-05-06 | 2024-06-04 | BioVersys AG | Antimicrobials methods of making and using the same |
US11155558B2 (en) | 2017-05-22 | 2021-10-26 | Topadur Pharma Ag | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
RU2758373C2 (ru) * | 2017-05-22 | 2021-10-28 | Топадур Фарма Аг | Новые активаторы растворимой гуанилатциклазы и ингибиторы фосфодиэстеразы с двойным механизмом действия и их применение |
AU2018274599B2 (en) * | 2017-05-22 | 2022-03-03 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
AU2018274599B9 (en) * | 2017-05-22 | 2022-04-07 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
IL269835B (en) * | 2017-05-22 | 2022-08-01 | Topadur Pharma Ag | Novel dual-acting soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses |
WO2018215433A1 (en) | 2017-05-22 | 2018-11-29 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
US11905293B2 (en) | 2017-05-22 | 2024-02-20 | Topadur Pharma Ag | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
WO2020030489A1 (en) | 2018-08-06 | 2020-02-13 | Nicox S.A. | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
WO2020109354A1 (en) | 2018-11-28 | 2020-06-04 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
WO2023052407A1 (en) | 2021-09-29 | 2023-04-06 | Topadur Pharma Ag | Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof |
KR20230129639A (ko) | 2022-03-02 | 2023-09-11 | 연세대학교 산학협력단 | 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태 |
WO2023167503A1 (ko) * | 2022-03-02 | 2023-09-07 | 연세대학교 산학협력단 | 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태 |
WO2023166013A1 (en) | 2022-03-02 | 2023-09-07 | Topadur Pharma Ag | Topical compositions and uses therof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1257553B1 (de) | Pyrrolopyrimidinon-derivate, verfahren zu ihrer herstellung und verwendung | |
AU2001236140A1 (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
AU744388B2 (en) | 1H-imidazopyridine derivatives | |
US5260303A (en) | Imidazopyridines as serotonergic 5-HT3 antagonists | |
KR20020038963A (ko) | P38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환 | |
KR20010092754A (ko) | Xa 인자 억제제로서의 질소 함유 헤테로비시클릭 화합물 | |
EP1323719A1 (de) | Thienopyrimidin-Verbindungen und Verfahren zu ihrer Herstellung | |
US20060235020A1 (en) | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein | |
CA1288097C (en) | 2-substituted-e-fused-¬1,2,4|triazolo-¬1,5- c|pyrimidines pharmaceutical compositions and uses thereof | |
FI64597C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-ubstituerade 1,2-dihydro-3h-pyrrolo(1,2-a)pyrrol-1-karbox ylyror av motsvarande nya nitriler | |
US5280029A (en) | Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof | |
KR20110028445A (ko) | 퇴행성 및 염증성 질병의 치료에 유용한 축합된 피라진 화합물 | |
US20050075376A1 (en) | Cycloalkyl heterocycles for treating Hepatitis C virus | |
EP0557526B1 (de) | Pyrroloazepinverbindungen | |
NZ243595A (en) | Imidazo[2,1-b]benzothiazole-3-acetamide derivatives and pharmaceutical compositions | |
WO2001087888A1 (en) | Pyrazolopyrimidinone derivatives, process for their preparation and their use | |
US20030153558A1 (en) | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | |
KR100297814B1 (ko) | 피라졸로피리미디논유도체와이의제조방법그리고이의용도 | |
US5227377A (en) | Meso-azacyclic amides of certain bicyclic carboxylic acids | |
TWI300778B (en) | Pyrrolopyrimidinone derivatives, process of preparation and use | |
US20050130983A1 (en) | Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them | |
HU188071B (en) | Process for producing pyrrolo-benzodiazepine derivatives | |
JP2000513013A (ja) | ピロロピロロン誘導体 | |
EP1362858A1 (de) | Pyrrolopyrimidinonderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 151234 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2400268 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007942 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2001 560209 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/06587 Country of ref document: ZA Ref document number: 200206587 Country of ref document: ZA Ref document number: 520842 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001908397 Country of ref document: EP Ref document number: 2001236140 Country of ref document: AU Ref document number: IN/PCT/2002/00819/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/00852/DE Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002124872 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018075002 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001908397 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10204327 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 520842 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001908397 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 520842 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001236140 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001236140 Country of ref document: AU |